Several other research firms have also commented on REGN. Leerink Swann reissued a positive rating and set a $552.00 price target (down from $580.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 15th. Piper Jaffray Companies reissued an overweight rating and set a $557.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 1st. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, October 10th. Jefferies Group LLC reissued a hold rating and set a $500.00 price target (up from $471.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, October 6th. Finally, Robert W. Baird reissued a sell rating and set a $408.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, September 8th. Three analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of Hold and an average price target of $489.92.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 440.94 on Monday. The company has a market capitalization of $46.75 billion, a price-to-earnings ratio of 44.24 and a beta of 1.62. Regeneron Pharmaceuticals has a 1-year low of $325.35 and a 1-year high of $543.55. The firm’s 50-day moving average is $452.90 and its 200-day moving average is $456.40.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company’s quarterly revenue was up 21.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.82 earnings per share. Analysts forecast that Regeneron Pharmaceuticals will post $14.94 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was posted by BBNS and is the sole property of of BBNS. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://baseballnewssource.com/markets/regeneron-pharmaceuticals-inc-regn-earns-hold-rating-from-j-p-morgan-chase-co/1719504.html.
In other news, major shareholder Sanofi acquired 166,415 shares of the firm’s stock in a transaction on Thursday, August 24th. The shares were bought at an average price of $480.93 per share, for a total transaction of $80,033,965.95. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Michael S. Brown sold 1,500 shares of the firm’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The disclosure for this sale can be found here. Insiders sold a total of 89,468 shares of company stock worth $42,312,448 in the last three months. 10.80% of the stock is owned by corporate insiders.
Hedge funds have recently made changes to their positions in the business. Oppenheimer & Co. Inc. lifted its holdings in Regeneron Pharmaceuticals by 20.6% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 7,007 shares of the biopharmaceutical company’s stock valued at $3,441,000 after purchasing an additional 1,199 shares in the last quarter. Dupont Capital Management Corp purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $220,000. Blair William & Co. IL lifted its holdings in Regeneron Pharmaceuticals by 4.8% in the 2nd quarter. Blair William & Co. IL now owns 1,713 shares of the biopharmaceutical company’s stock valued at $841,000 after purchasing an additional 79 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 2.4% in the 2nd quarter. Principal Financial Group Inc. now owns 115,201 shares of the biopharmaceutical company’s stock valued at $56,580,000 after purchasing an additional 2,646 shares in the last quarter. Finally, National Pension Service lifted its holdings in Regeneron Pharmaceuticals by 10.8% in the 2nd quarter. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock valued at $33,920,000 after purchasing an additional 6,481 shares in the last quarter. Institutional investors own 67.40% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.